Description
Anti-PCSK9 Antibody, Non-Fucosylated (BioBet-405ZP) is a humanized monoclonal IgG1, κ antibody against PCSK9. This product is an ADCC enhanced antibody produced by our Afuco™ platform.
Antibody Indication
Atherosclerosis
Classification
Therapeutic antibody; biobetter
Cooperation Seeking
Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced PCSK9 antibody. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Official Name
PCSK9
Full Name
Proprotein Convertase Subtilisin/Kexin Type 9
Background
This gene encodes a member of the subtilisin-like proprotein convertase family, which includes proteases that process protein and peptide precursors trafficking through regulated or constitutive branches of the secretory pathway. The encoded protein undergoes an autocatalytic processing event with its prosegment in the ER and is constitutively secreted as an inactive protease into the extracellular matrix and trans-Golgi network. It is expressed in liver, intestine and kidney tissues and escorts specific receptors for lysosomal degradation. It plays a role in cholesterol and fatty acid metabolism. Mutations in this gene have been associated with autosomal dominant familial hypercholesterolemia. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Feb 2014]
Alternative Names
PCSK9 inhibitors; PCSK9; proprotein convertase subtilisin/kexin type 9; HCHOLA3, hypercholesterolemia, autosomal dominant 3; FH3; NARC 1; NARC1; NARC-1; HCHOLA3;
Gene ID
353175
UniProt ID
Q8NBP7
Cellular Localization
Extracellular region or secreted, Golgi apparatus, Endosome, Lysosome, Endoplasmic reticulum
Involvement in Disease
Diseases associated with PCSK9 include Hypercholesterolemia, Familial, 3 and Familial Hypercholesterolemia.
Related Pathways
Its related pathways are Neuroscience and Lipoprotein metabolism.
Function
Play a key role in regulating plasma cholesterol homeostasis. With members of the low density lipid receptor family: low density lipoprotein receptor (LDLR), very low density lipoprotein receptor (VLDLR), apolipoprotein E receptor (LRP1/APOER) and apolipoprotein receptor 2 ( The combination of LRP8/APOER2) promotes its degradation in the acidic compartment of the cell. Through a non-proteolytic mechanism, through the clathrin LDLRAP1/arh-mediated pathway, enhance the degradation of liver LDLR. It may prevent LDLR from circulating from endosomes to the cell surface or direct it to lysosome degradation. Can induce ubiquitination of LDLR, leading to its degradation. The autophagosome/lysosome pathway inhibits APOB degradation in cells in a ldlr-independent manner. Involved in processing the non-acetylated intermediates of BACE1 in the early secretory pathway. Inhibition of epithelial Na(+) channel (ENaC)-mediated Na(+) absorption, mainly by increasing the proteasome degradation of ENaC to reduce its surface expression. Regulate neuronal apoptosis by regulating LRP8/APOER2 levels and related anti-apoptotic signaling pathways. 发送反馈 历史记录
Field of research
Cell Biology and Cellular Response antibody; Developmental Biology antibody; Metabolism antibody; Signaling Transduction antibody
Post-translational modifications
Cleavage by furin and PCSK5 generates a truncated inactive protein that is unable to induce LDLR degradation. Undergoes autocatalytic cleavage in the endoplasmic reticulum to release the propeptide from the N-terminus and the cleavage of the propeptide is strictly required for its maturation and activation. The cleaved propeptide however remains associated with the catalytic domain through non-covalent interactions, preventing potential substrates from accessing its active site. As a result, it is secreted from cells as a propeptide-containing, enzymatically inactive protein. Phosphorylation protects the propeptide against proteolysis.
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Antibody Isotype
IgG1, κ
Antibody Clone
BioBet-405ZP
Description
ADCC-enhanced Lodelcizumab is a non-fucosylated anti-PCSK9 therapeutic biobetter antibody.
Antibody Indication
Atherosclerosis
